Atherosclerosis describes the build-up of fats, cholesterol and other substances in and on the artery walls, potentially reducing or completely blocking the arterial blood flow as Critical Limb Ischemia (CLI). With 3.5M patients in Europe, today's CLI treatment approaches of arterial widening (angioplasty) and bypass surgery are unsatisfactory, with ~40% of patients experiencing repeat procedures. In an European consortium together with ProVascTec (Cork, Ireland) and Cellcolabs (Stockholm, Sweden), we develop a new stent-based treatment solution (nufloCelTx). Pro-angiogenic MSCs are embedded in an electrospun, biodegradable scaffold to help stimulate the development of new blood vessels, and when delivered directly to the target area via an artery, effectively establish a natural bypass around the arterial blockage.